Vaxin Inc. is an emerging biotechnology company developing vaccines and other biological products to address market and public health needs. The company uses proprietary technology for non-invasive delivery to the nasal passages or to the skin, and has shown proof of principle in animals and in initial human clinical studies.

Vaccines, once considered commodity products, have become one of the largest growth areas in health care. The global vaccine market was approximately $7.7B in 2002, and is expected to grow at 13% annually to $17B in 2010. Merrill Lynch projects influenza sales alone to approach $2B in 2007. The increase in annual sales is being fueled by:

• New vaccines to address previously unmet needs

• Improved vaccines which warrant higher per dose pricing and lead to greater usage

• Trends in health care economics, preventative medicine, and public-health policy leading to greater usage

Vaxin believes that it is well positioned to participate in this market growth with both novel products and products that provide significant improvement over currently marketed products. The company’s products use proprietary, safe, non-replicating adenovirus or bacterial vectors to deliver vaccine antigens (proteins) to the nasal mucosa or to the skin (topically) where they stimulate a protective immune response. Additional advantages of Vaxin’s technologies include lower cost, high-yield manufacturing, and long-term product stability.

The company’s lead programs include vaccines for Influenza, Anthrax, Avian Influenza, Tetanus, and Alzheimer.